SFEBES2025 Meet the Expert Sessions Advances in medical therapy for Graves’ ophthalmopathy (1 abstracts)
Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom
The management of thyroid eye disease has evolved significantly over the last 5-10 years. While methylprednisolone remains the mainstay of treatment for patients with active, moderate to severe disease, newer immunotherapies are changing how we manage this heterogeneous condition. Emerging therapeutic options add complexity to management decisions, but have the potential to hugely benefit our patients.